Resolvin D5
Based on 1 Customer Validation
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.3%
- CAS. Nr.: 578008-43-2
- Formel: C22H32O4
- Molecular Weight:360.49
-
Speicherung:
-80°C
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Resolvin D5 (100, 500 nM; 3-5 days) suppresses Th17 cell differentiation and facilitates Treg differentiation in CD4+ T cells isolated from SKG mouse spleens in a concentration-dependent manner[1].
Resolvin D5 (1-100 nM; 3 days) suppresses the proliferation of CD4+ T cells isolated from SKG mouse spleens in a concentration-dependent manner, with 100 nM inducing a significant reduction in proliferating cells[1].
Resolvin D5 (10-500 nM; 3 days) suppresses RANKL-induced osteoclast differentiation in bone marrow-derived macrophages from SKG mice in a concentration-dependent manner, with 10, 100, and 500 nM concentrations reducing TRAP+ MNC formation and downregulating key osteoclastogenesis-related genes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Th17 cell
-
Concentration:1, 10, 100, 500 nM
-
Incubation Time:3-5 days
-
Result:Suppressed Th17 cell differentiation and facilitates Treg differentiation in CD4+ T cells isolated from SKG mouse spleens in a concentration-dependent manner (100-500 nM).
Resolvin D5 (100 ng; i.t.; single dose) produces a transient, male-specific reduction in chemotherapy-induced mechanical allodynia in wild-type, Trpv1 knockout, and Trpa1 knockout mice, with no analgesic effect in female mice[2].
Resolvin D5 (10 ng; i.t.; single dose) produces a male-specific reduction in formalin-induced Phase II inflammatory pain, with no analgesic effect in female mice or on Phase I pain responses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 mice with Chemotherapy-induced peripheral neuropathy (male and female, adult, 25-35 g); B6.129X1-Trpv1tm1Jul/J (male and female, Trpv1 knockout); B6;129P-Trpa1tm1Kykw/J (male and female, Trpa1 knockout)[2]
-
Dosage:100 ng
-
Administration:i.t.; single dose
-
Result:Significantly increased paw withdrawal threshold (reduced mechanical allodynia) in male wild-type, male Trpv1 knockout, and male Trpa1 knockout mice at 1 hour post-injection, with effects diminished by 3 hours post-injection.
Showed no significant change in paw withdrawal threshold in female wild-type, female Trpv1 knockout, or female Trpa1 knockout mice at any time point post-injection.
-
Animal Model:CD1 mice with Inflammatory pain (male and female, adult, 25-35 g)[2]
-
Dosage:10 ng
-
Administration:i.t.; single dose
-
Result:Significantly reduced the duration of licking and flinching during the Phase II inflammatory pain response (10-45 minutes post-formalin) in male mice, with no significant effect on Phase I pain behavior (0-10 minutes post-formalin).
Showed no significant change in Phase I or Phase II pain behavior in female mice.
Chemical Information
-
CAS. Nr. 578008-43-2
-
Appearance Liquid
-
Molecular Weight 360.49
-
Formel C22H32O4
-
Color Colorless to light yellow
-
SMILES
CC/C=C\C[C@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)C/C=C\CCC(O)=O
-
Structure Classification
-
Initial Source
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C
Reinheit & Dokumentation
-
Data Sheet (268 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Yamada H, et al. Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis. Sci Rep. 2021;11(1):17312. Published 2021 Aug 27. [Content Brief]
[2]. Luo X, et al. Resolvin D5 Inhibits Neuropathic and Inflammatory Pain in Male But Not Female Mice: Distinct Actions of D-Series Resolvins in Chemotherapy-Induced Peripheral Neuropathy. Front Pharmacol. 2019;10:745. Published 2019 Jul 5. [Content Brief]
[3]. Chun HW, et al. Resolvin D5, a Lipid Mediator, Inhibits Production of Interleukin-6 and CCL5 Via the ERK-NF-κB Signaling Pathway in Lipopolysaccharide-Stimulated THP-1 Cells. J Microbiol Biotechnol. 2020;30(1):85-92. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Resolvin D5 Related Classifications
HY-145491 Related Classifications
Powered by Bioz